Obeticholic acid
Class
Cholelitholytics
Subclass
Semisynthetic bile acids
Generic name
Obeticholic acid
Brand names
Ocaliva®
Common formulations
Film-coated tablet
Dosage and administration
Adults patients
Treatment of primary biliary cholangitis
Indications for use
Labeled indications
Adults
Safety risks
Boxed warnings
ALF, decompensated liver disease
ALF, decompensated liver disease, portal hypertension
Contraindications
Compensated cirrhosis with evidence of portal hypertension (e.g., ascites, gastroesophageal varices, persistent thrombocytopenia)
Complete biliary obstruction
Decompensated cirrhosis (Child-Pugh Class B or C) or a prior decompensation event
Warnings and precautions
Generalized pruritus, decreased serum HDL
Specific populations
Renal impairment
eGFR ≥ 15 mL/min/1.73 m²
eGFR < 15 mL/min/1.73 m²
Renal replacement therapy
Any modality
Hepatic impairment
Acute or decompensated chronic liver disease
Child-Pugh A (mild)
Child-Pugh B (moderate)
Child-Pugh C (severe)
Pregnancy and breastfeeding
Pregnancy
All trimesters • Australia Category: B1
Breastfeeding
Little information available on breastfeeding safety.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
Common 1-10%
Unknown frequency
Interactions
Drug(s)
Check Interactions
Reset
What did you think about this content?
Sign up for free to access the full drug resource